Navigation Links
CerviLenz Receives JumpStart Investment
Date:5/15/2008

CLEVELAND, May 15 /PRNewswire/ -- JumpStart Inc., the Northeast Ohio venture development organization that accelerates the growth of innovative early-stage businesses and ideas, has announced an investment commitment of $350,000 in CerviLenz(TM), Inc. The Cleveland-based company is commercializing a patented, Federal Drug Administration cleared medical device that allows obstetricians to easily measure cervical length in pregnant women, which has been established by the National Institutes of Health as an effective predictor of preterm birth risk.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060209/CLJUMPSTARTLOGO )

According to the American College of Obstetricians and Gynecologists, patients at high risk for preterm births have been difficult to identify and have accounted for more than $2 billion in annual healthcare costs.

"Until recently, the causes of preterm birth have been poorly understood with few existing treatment options available," said Kevin Mendelsohn, the JumpStart Entrepreneur-in-Residence who will be working with the company. "But the recent emergence of progesterone as a therapy to substantially reduce the risk of preterm birth has presented a significant opportunity for CerviLenz. Its medical device provides obstetricians and gynecologists a cost effective alternative to screen women for preterm birth risk and determine whether they are suitable candidates for the therapy or to consult with a high-risk pregnancy specialist," Mendelsohn concluded.

CerviLenz is led by Board Chairman Dr. Michael Ross, a Maternal-Fetal Medicine specialist and Chairman of Obstetrics and Gynecology at Harbor-UCLA Medical Center, and Chief Executive Officer Dean Koch, an industry veteran who has spent the past 10 years with Adeza Biomedical, the first firm in the preterm birth arena. Together, Dr. Ross and Mr. Koch bring extensive clinical experience and highly relevant sales and marketing experience in the preterm birth market.

"Preterm birth has a profound effect on babies and their families alike. CerviLenz provides an opportunity for improved management of this significant, unmet medical need, and I am personally committed to help reduce its incidence in the United States and abroad," said Koch.

According to Koch, more than one in eight pregnant women will deliver their baby preterm, which is defined as delivery before 37 completed weeks of gestation, and most often as a surprise to both the women and their physicians. The rate of preterm birth in the United States has increased over 30 percent since 1980; however, new research with progesterone is predicted to reverse this trend.

"In published work from the National Institutes of Health and others, progesterone therapy has been shown to reduce preterm birth risk, particularly in women with a short cervix," Koch continued. "Translating such groundbreaking work from the research setting to the real world will present many challenges. The CerviLenz device will help physicians, midwives and nurses to easily and cost effectively identify pregnant women at high risk of preterm birth and get them the care they need to reduce the risk of delivering their baby early."

The company is utilizing JumpStart's investment to help complete clinical studies, conduct additional market research, and engage in pre-launch marketing efforts.

This is JumpStart's 40th investment in its 29th company. Other healthcare companies in JumpStart's portfolio include AcelleRx Therapeutics, AnalizaDx, CardioInsight Technologies, Great Lakes Pharmaceuticals, Synapse Biomedical and Telerad Express.

About CerviLenz, Inc.

CerviLenz(TM), Inc., headquartered near Cleveland, Ohio, is a manufacturer and marketer of a patented, FDA cleared device to predict preterm birth risk in pregnant women by accurately measuring cervical length. Preterm birth (delivery prior to 37 completed weeks of gestation) affects almost 13 percent of pregnancies annually in the United States, representing over 500,000 babies. It is a serious health problem, with increased risk for a variety of newborn complications and lifelong disabilities. Preterm birth is also the leading cause of infant death. Cervical length was established by the National Institutes of Health as a powerful predictor of preterm birth risk in a study utilizing a specialized ultrasound probe and technique. The CerviLenz device is a simple, low cost alternative that can be used by a healthcare professional to identify women who may benefit from progesterone therapy or further consultation by a specialist.

About JumpStart Inc.

JumpStart (http://www.jumpstartinc.org ) accelerates the growth of innovative early-stage businesses and ideas into venture-ready companies by delivering vital, focused resources to entrepreneurs and the community of Northeast Ohio. JumpStart identifies and invests in early-stage companies that have strong potential in the marketplace, solid prospects for high growth, and are likely to qualify for later-stage funding. Beyond investing, the JumpStart team provides a continuum of business development services to its client companies to help ensure their success.


'/>"/>
SOURCE JumpStart Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III
2. Cancer Centers of North Carolina Receives Prestigious Accreditation
3. Fox Chase Cancer Centers Ning Wong receives ASCO Cancer Foundation Career Development Award
4. Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin
5. Haemacure financing receives shareholder consent - Series B Warrants are amended
6. Gladney Center for Adoption Receives Whole Health Grant from Aetna Foundation
7. Novalar Receives FDA Approval for OraVerse(TM)
8. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
9. U.S. Navy Receives Funding for Further Development of Hemopure(R)
10. UCSF receives funding for building from California stem cell agency
11. USC receives nearly $27 million in funding for new stem cell research facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Youth Futures ... great success and feedback from high school and college students who have participated in ... held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... Louisiana (PRWEB) , ... March 29, 2017 , ... ... in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of ... Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the counter ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology: